|1.||Oh, Eok-Soo: 14 articles (02/2015 - 08/2002)|
|2.||Modrowski, Dominique: 6 articles (01/2015 - 08/2005)|
|3.||Han, Inn-Oc: 6 articles (05/2014 - 10/2009)|
|4.||Park, Haein: 6 articles (12/2009 - 08/2002)|
|5.||Choi, Youngsil: 5 articles (02/2015 - 01/2010)|
|6.||Choi, Sojoong: 5 articles (02/2015 - 10/2009)|
|7.||Marie, Pierre J: 5 articles (01/2015 - 08/2005)|
|8.||Han, Innoc: 5 articles (02/2013 - 08/2002)|
|9.||Chung, Heesung: 4 articles (05/2014 - 10/2009)|
|10.||Kim, Yeonhee: 4 articles (02/2013 - 08/2002)|
02/13/2003 - "In contrast, syndecan-2 expression was dramatically reduced and it was correlated with the morphological changes of colon carcinoma cells. "
08/01/2014 - "Syndecan-2 regulation of morphology in breast carcinoma cells is dependent on RhoGTPases."
07/01/2010 - "Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma."
03/01/2004 - "New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells."
02/13/2003 - "All these results indicate that reduced syndecan-2 expression correlates with TSA-induced morphological changes and reduced tumorigenic activity in colon carcinoma cells."
01/01/2014 - "Syndecan 2 levels were very low or undetectable in healthy tissues, increasing significantly in well-differentiated tumors, and decreasing in poorly differentiated NETs, and its expression levels showed a positive correlation with patient survival. "
05/01/2013 - "Syndecan-2 expression in non-malignant stroma was higher in CSCC than in OSCC tumors. "
06/01/2012 - "Here, we show that syndecan-2 has a stronger tumor suppressor activity in vivo. "
05/01/2011 - "First, we assessed the selectivity of AG73-Dox for cancer cells, including syndecan-2 over-expressing cells, using flow cytometry and confocal microscopy. "
08/01/2010 - "AG73 peptide is well known as a ligand for syndecan-2 which is highly expressed in various cancer cells. "
|3.||Colonic Neoplasms (Colon Cancer)
08/16/2002 - "Cell biological studies using the extracellular domain of recombinant syndecan-2 (2E) or spreading assay with syndecan-2 antibody-coated plates showed that syndecan-2 mediated adhesion and cytoskeletal organization of colon cancer cells. "
08/16/2002 - "In this study, we examined the function of syndecan-2 in colon cancer cell lines. "
02/28/2015 - "Taken together, these results demonstrate that shed syndecan-2 directly enhances colon cancer progression and may be a promising therapeutic target for controlling colon cancer development. "
02/28/2015 - "Shed syndecan-2 enhances tumorigenic activities of colon cancer cells."
04/04/2014 - "Here, we demonstrate a role for interleukin-1α (IL-1α) in syndecan-2 shedding in colon cancer cells. "
|4.||Osteosarcoma (Osteogenic Sarcoma)
08/01/2005 - "In this study, we examined the role of syndecan-2 in osteosarcoma cell proliferation and apoptosis. "
10/01/2012 - "We previously showed that Wnt/β-catenin/T-cell factor (TCF) activation are responsible for the repression of syndecan-2, a key modulator of apoptosis and chemosensitivity in osteosarcoma cells, suggesting a role of Wnt signaling in chemoresistance. "
07/01/2010 - "Our results identify syndecan-2 as a Wnt target and bring new insights into a possible pathologic role of Wnt signaling in osteosarcoma."
07/01/2010 - "The high activity of the canonical Wnt pathway in the different osteosarcoma cells induces a constitutive repression of syndecan-2 transcription, whereas Wnt/RhoA signaling blocks the amplification loop of syndecan-2 expression. "
07/01/2010 - "The alteration of syndecan-2 expression in osteosarcoma cell lines also seemed to be related to a higher shedding, controlled by Wnt/RhoA. "
|5.||Neoplasm Metastasis (Metastasis)
09/21/2007 - "This correlation was proved to be a causal relationship, because transfection of syndecan-2 into the higher metastatic clone resulted in the suppression of both spontaneous and experimental metastases to the lung. "
09/01/2014 - "Furthermore, high expression of CASK and syndecan-2 was significantly correlated with advanced tumor stage, lymphatic invasion, lymph node metastasis, vascular invasion, liver metastasis, and unresectable metastatic CRC. "
09/21/2007 - "Actually, MMP-2 was found to exhibit a strong binding ability to heparin, the dissociation constant value being 62 nM. These results indicate a novel function of syndecan-2, which acts as a suppressor for MMP-2 activation, causing suppression of metastasis in at least the metastatic system used in the present study."
01/01/2012 - "Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2."
09/21/2007 - "A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis."
|1.||Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)
|2.||Syndecan-1 (Syndecan 1)
|7.||Heparitin Sulfate (Heparan Sulfate)
|10.||GTP Phosphohydrolases (GTPases)
|2.||Drug Therapy (Chemotherapy)